<DOC>
	<DOCNO>NCT00003466</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : This phase II trial study well temozolomide work treat patient progressive low-grade glioma .</brief_summary>
	<brief_title>Temozolomide Treating Patients With Progressive Low-Grade Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Assess response rate patient progressive low-grade glioma treat temozolomide . - Determine activity drug , term stabilize growth progressive low-grade glioma , adult patient . OUTLINE : Patients stratify disease type ( pilocytic astrocytoma , mixed glioma , well-differentiated oligodendroglioma , nonbiopsied optic pathway glioma pontine glioma ) . Patients receive temozolomide orally daily day 1-5 . Courses repeat every 28 day . In absence disease progression unacceptable toxicity , patient may continue treatment tumor remain stable 12 course . Patients follow every 8-12 week 2 year . PROJECTED ACCRUAL : A total 36-100 patient ( 9-25 per stratum ) accrue study within 3 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm progressive , primary , intracranial , supratentorial , lowgrade glioma include : Astrocytoma Oligodendroglioma Mixed glioma Optic pathway glioma* Pontine glioma* NOTE : *Biopsy require Patients optic pathway glioma must also meet follow criterion : Progressive loss vision define double octave Visual acuity loss explain cause Increase proptosis great 3 mm Increase diameter optic nerve least 2 mm neuroimaging Increase distribution tumor involve optic tract optic radiation indicate CT scan MRI PATIENT CHARACTERISTICS : Age : 4 Performance status : Karnofsky 70100 % Life expectancy : More 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT SGPT less 2.5 time ULN Alkaline phosphatase less 2 time ULN Renal : Creatinine le 1.5 time ULN BUN less 1.5 time ULN Other : Must neurologically stable No systemic disease No acute infection require IV antibiotic No frequent vomit No medical condition would interfere oral medication ( e.g. , partial bowel obstruction ) No prior concurrent malignancy except : Surgically cure carcinoma situ cervix Basal squamous cell skin cancer HIV negative No AIDSrelated illness Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy ( growth factor epoetin alfa ) Chemotherapy : At least 6 week since prior chemotherapy unless evidence disease progression No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 6 week since prior radiotherapy unless evidence disease progression No concurrent radiotherapy Surgery : At least 3 week since prior surgery unless evidence disease progression Recovered prior surgery Other : No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>childhood mixed glioma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>untreated childhood visual pathway hypothalamic glioma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
</DOC>